Inmarsat: Greener Flights Coming to Italy Soon as ITA Airways to Join Iris Air Traffic Modernisation Programme
9.3.2023 10:00:00 EET | Business Wire | Press release
Digitally-connected flights to and from Italy will be available from this summer, as ITA Airways rolls out the European Space Agency (ESA) and Inmarsat’s ground-breaking Iris data link technology to the cockpits of its full aircraft fleet, contributing to airspace modernisation in Europe.
ITA Airways will be the first full service carrier in Europe to join Iris. The programme enables aircraft to fly more fuel-efficient routes by providing digital satellite communications to complement VHF data link, which is nearing a capacity crunch in congested airspace. Without fast and reliable data links between aircraft and the ground, air traffic managers cannot unlock the 8-10% reduction in CO2 emissions identified by EUROCONTROL from improved Air Traffic Management (ATM). Iris will allow ATM players to better anticipate and collaborate to maximise airspace use, reducing the impact of disruptions for passengers while reducing emissions.
The Italian national carrier will equip its full fleet of new Airbus A320neo and A330neo aircraft deliveries with Inmarsat’s SwiftBroadband-Safety (SB-S), the award-winning platform flying on more than 230 aircraft globally, which powers Iris. Its aircraft will also play a significant role in Iris demonstration flights, which will take place across European airspace supported by 14 Air Navigation Service Providers (ANSPs) during 2023.
This news comes as five more airlines have now equipped aircraft with Inmarsat SB-S, after Airbus’ Light Cockpit Satcom (LCS) terminal became available to order in December 2022. Current SB-S users include Virgin Atlantic, Jet2, and Transavia Airlines, in addition to ITA Airways and easyJet.
Across the seven European airlines, 72 aircraft deliveries with Airbus LCS installed are anticipated during 2023-2024. Iris-capable Inmarsat terminals across many more of Europe’s commercial airlines will further support the Single European Sky ATM Research (SESAR) masterplan.
Alessio Leone, Head of Camo Operations, at ITA Airways said “ITA Airways was born to guarantee Italy quality connectivity with a strong focus on the environmental impact through an important investment made in a homogeneous and technologically advanced fleet, which in 2026 will be made up of 80% of new generation aircrafts becoming the greenest fleet in Europe. We are proud to join the Iris programme, which is fully in line with our growth strategy as it reflects two of the core pillars of ITA Airways: sustainability and innovation. ITA Airways is the first full service carrier in Europe with a new fleet fully equipped with this cutting-edge technology by Inmarsat Aviation, delivering operational and environmental benefits.”
Joel Klooster, Inmarsat Aviation’s Senior Vice President of Aircraft Operations and Safety, said “We are delighted to welcome ITA Airways as the second airline to join Iris, coming only months after easyJet was announced as the first airline. This shows the impressive momentum that continues to build around the programme as it heads towards commercial service introduction in Europe this year, followed by a full global rollout. Iris will mark a transformational step-change in air traffic management, delivering operational and environment benefits for airlines and the aviation industry as a whole, while also enhancing the flight experience for passengers.”
Javier Benedicto, Acting Director of Telecommunications and Integrated Applications at ESA, said: “We are proud to support the space-enabled digitalisation of Europe’s skies, which will help to make aviation greener. ESA developed the Iris system in partnership with Inmarsat and we welcome ITA Airways as the first full service carrier and the second airline to sign up to use it. Investing in space improves life on Earth.”
ENDS
NOTES TO EDITORS:
ITA follows easyJet, which became the first airline to join the programme last June.
ABOUT ITA AIRWAYS
ITA Airways is a company totally owned by the Italian Ministry of Economy and Finance for the exercise of business in the air transport sector. ITA Airways aims at creating an efficient and innovative air carrier that will become a reference point in providing Italy with quality connectivity both in terms of international destinations, thus boosting tourism and foreign trade, and within the Country, also taking advantage of the train-air integrated mobility. ITA Airways will place the best customer service at the center of its strategy (through a strong digitization of processes that ensure a best-in-class experience and personalized services), combined with sustainability, in its environmental (new green and technologically advanced aircraft, use of sustainable fuels), social (equality and inclusion for a gender-neutral company) and governance (integration of sustainability into internal strategies and processes) aspects. ITA Airways is a member of SkyTeam alliance as of October 2021.
ABOUT INMARSAT
Inmarsat delivers world leading, innovative, advanced and exceptionally reliable global, mobile communications across the world – in the air, at sea and on land - that are enabling a new generation of commercial, government and mission-critical services. Inmarsat is powering the digitalisation of the maritime industry, making operations more efficient and safer than ever before. It is driving a new era of inflight passenger services for aviation, while ensuring that aircraft can fly with maximum efficiency and safety. Furthermore, Inmarsat is enabling the rapid expansion of the Internet of Things (IoT) and enabling the next wave of world-changing technologies that will underpin the connected society and help build a sustainable future. And now Inmarsat is developing the first-of-its-kind, multi-dimensional communications network of the future, ORCHESTRA.
In November 2021, Inmarsat and Viasat announced the planned combination of the two companies, to create a new leader in global communications.
For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.
ABOUT IRIS
Iris benefits airlines and ANSPs by bringing the bandwidth and reliability to allow digital exchanges between the aircraft and ground systems. System-to-system digital communication enables flights to be managed more efficiently through trajectory-based operations. These 4 Dimensional Trajectory-Based Operations (4D TBO) improve the management of airspace capacity, unlocking operational efficiency for airlines by avoiding holding patterns, accessing improved routes and optimum altitudes, and using continuous climb and descent pathways. The additional datalink capacity provided by SB-S will also power a host of onboard digital applications, such as AI flight profile optimisers and real-time weather applications.
European Union Aviation Safety Agency (EASA) certification of ESSP as the Communication Service Provider for the Iris data link service is nearing completion, and will mark the first air navigation service provider to own a pan-European certificate that allows cross-border delivery of air traffic management services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005515/en/
Contact information
Inmarsat
press@inmarsat.com
ITA Airways
Nicolò Mardegan
Head of Communication and Institutional Relations
media@ita-airways.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
